A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) (ISLAND-SLE)
J1P-MC-KFAJ - ClinicalTrials.gov - NCT04433585
The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
Trial Summary
Age Range
18 - 65 yearsConditions the trial is for
Lupus (SLE)What the trial is testing?
LY3471851Could I receive a Placebo?
YesEnrollment Goal
291Trial Dates
Aug 19, 2020 - Feb 16, 2023How long will I be in the trial?
The study will last about 43 weeks and may include up to 17 visits.Trial Phase
IIKey Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have had systemic lupus erythematosus (SLE or lupus) for at least 6 months
Participants must have currently active manifestations of lupus
Participants must have active arthritis and/or rash
Participants Must Not:
Participants must not have severe lupus nephritis
Participants must not have severe central nervous system lupus
Participants must not have or have had another serious medical condition
Lilly Trial Alerts
Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
Clinical Trial Resources
You will complete the questionnaire on another website.YesNo